Amphastar Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Amphastar Pharmaceuticals, Inc. (AMPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-06-30 was 0.00%.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-09-30 was 0.00%.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-06-30 was 0.00%.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2015 was 0.00%.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2014 was 0.00%.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2013 was 0.00%.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2012 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-06 | 0.00% 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-07 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-06 | 0.00% 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | 0.00% 10-Q · filed 2026-08-06 | 0.00% 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | 0.00% 10-Q · filed 2026-05-07 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-07 | 0.00% 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | 0.00% 10-Q · filed 2025-08-07 | 0.00% 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | 0.00% 10-Q · filed 2025-05-08 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-07 | 0.00% 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-09 | 0.00% 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | 0.00% 10-Q · filed 2024-05-10 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-08 | 0.00% 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-09 | 0.00% 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-09 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2022-11-08 | 0.00% 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | 0.00% 10-Q · filed 2022-08-09 | 0.00% 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | 0.00% 10-Q · filed 2022-05-10 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-09 | 0.00% 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | 0.00% 10-Q · filed 2021-08-09 | 0.00% 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | 0.00% 10-Q · filed 2021-05-07 | |||
| 2019-09-30 | 0.00% 10-Q · filed 2020-11-06 | 0.00% 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | 0.00% 10-Q · filed 2020-08-07 | 0.00% 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | 0.00% 10-Q · filed 2020-05-11 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2019-11-08 | 0.00% 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | 0.00% 10-Q · filed 2019-08-09 | 0.00% 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-10 | |||
| 2017-09-30 | 0.00% 10-Q · filed 2018-11-09 | 0.00% 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-09 | 0.00% 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | 0.00% 10-Q · filed 2018-05-10 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2017-11-09 | 0.00% 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | 0.00% 10-Q · filed 2017-08-09 | 0.00% 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | 0.00% 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | 0.00% 10-K · filed 2016-03-15 | |||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-09 | 0.00% 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | 0.00% 10-Q · filed 2016-08-09 | 0.00% 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | 0.00% 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | 0.00% 10-K · filed 2016-03-15 | |||
| 2014-09-30 | 0.00% 10-Q · filed 2015-11-13 | 0.00% 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | 0.00% 10-Q · filed 2015-08-13 | 0.00% 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | 0.00% 10-Q · filed 2015-05-14 | |||
| 2013-12-31 | 0.00% 10-K · filed 2016-03-15 | |||
| 2013-09-30 | 0.00% 10-Q · filed 2014-11-13 | 0.00% 10-Q · filed 2014-11-13 | ||
| 2013-06-30 | 0.00% 10-Q · filed 2014-08-13 | 0.00% 10-Q · filed 2014-08-13 | ||
| 2012-12-31 | 0.00% 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |